In our study, we found that the rates of albumin deficiency (<35 g/L) and total serum protein deficiency (<65 g/L) increased significantly in the control group, and the mean albumin and total serum protein level in the control group were lower than the intervention group, especially for the colon cancer group and stage III–IV, suggesting that patients in the control group might have a worse prognosis in this study than those in the intervention group. The gene discussed is ALB; the disease is hereditary thrombophilia due to congenital protein S deficiency.